查看购物车
  • Traditional Chinese
  • Japanese
  • Korean
诊断学的生物标记市场 - 2031年前的世界策略性洞察能力与预测
市场调查报告书
商品编码
1812606

诊断学的生物标记市场 - 2031年前的世界策略性洞察能力与预测

Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031
出版日期: | 出版商: Kalorama Information | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

"诊断领域生物标记市场－全球策略洞察与2031年预测" 对2022年至2031年全球临床诊断生物标记市场进行了全面分析，并进行了预测。本报告研究了用于疾病检测、治疗选择、疾病监测和疗效评估的诊断试剂和检测，涵盖七大产品类别：传染病、癌症、心血管疾病、一般临床化学分析、神经系统疾病、自体免疫疾病、糖尿病、代谢紊乱、不孕症、怀孕、肾臟疾病、遗传性疾病和甲状腺疾病。

报告提供了每个类别及主要子类别的全球和地区销售数据，以及对美国、欧洲、中国、印度和日本的预测。所有市场价值均反映最终用户在生物标记相关试剂、检测试剂盒和耗材上的支出，不包括诊断设备的价值。数据是根据对製造商、实验室人员和行业专家的广泛一手访谈，以及政府统计数据、行业协会、公司文件和 Kalorama 出版物等二手资料。

本书探讨了关键的产业驱动因素，包括人口老化、标靶疗法的采用、不断扩大的诊断检测市场，以及质谱、新一代定序和生物资讯学等技术进步。本书也涵盖了生物标记在个人化和精准医疗中的作用、药物基因体学的趋势、自动化、报销和创新管道等主题。本书提供了详细的竞争分析，重点介绍了领先的体外诊断和生物标记纯业务公司，重点介绍了其商业化产品、新兴技术和市场定位。

"诊断市场中的生物标记——2031 年全球战略洞察与预测（肿瘤标誌物、肾病标誌物、遗传病标誌物、心臟标誌物、神经病学标誌物、自身免疫性疾病、传染病和其他标誌物）" 提供了详细的细分市场、市场趋势和战略洞察，对于在生物标誌物领域竞争的公司以及这一重要的公司

目录

第1章 简介

第2章 摘要整理

第3章 市场环境与分析

  • 概要
    • 人口动态模式
    • 总人口
    • 65岁以上的人口
    • 全球医疗保健趋势
    • 医疗费
    • 医院
    • 医生
    • 患者的活动
    • 住院
    • 外科手术
    • 门诊病人诊疗
    • 世界经济的气候
  • 生物标记技术
    • 人工智慧和机器学习在生物标记分析中日益重要的作用
  • 生物标记市场分析
    • 主要的市场趋势
    • 生物标记产品市场
    • 地理市场

第4章 感染疾病生物标记

  • 概要
  • 感染疾病生物标记技术
  • 感染疾病的主要生物标记
    • 呼吸系统疾病
    • COVID-19
    • 肺炎
    • 流感
    • A组链球菌感染
    • 结核病
    • 其他呼吸道感染
    • 医院相关感染 (HAI)
    • 艰难梭菌 (C. diff)
    • 败血症
    • 金黄色葡萄球菌
    • 肠球菌
    • 其他医源性感染
    • 肝炎
    • 爱滋病毒
    • 性传染病 (STD)
    • 人类乳突病毒 (HPV)
    • 披衣菌/淋病 (CT/NG)
    • 滴虫病
    • 单纯疱疹病毒 (HSV-1 和 HSV-2)
    • 其他性传染病
    • 梅毒
    • 龟头疳
    • 软下疳
    • 传染性软疣
    • 骨盆腔发炎 (PID)
    • 外阴蝨
    • 疥疮
    • 阴道炎
    • 火炬菌病
    • 其他传染病
    • 疟疾
    • 莱姆病
    • 幽门螺旋桿菌
    • 登革热
    • 所有其他疾病生物标记
    • 恰加斯病
    • 环孢子虫病
    • 囊虫病
    • 伊波拉病毒
    • 汉他病毒
    • 癣
    • 西尼罗河病毒 (WNV)
    • 寨卡病毒
    • 其他传染病生物标记销售
  • 市场分析
  • 生物标记产品供应商

第5章 癌症生物标记

  • 概要
  • 癌症的重要的生物标记
  • 最近的趋势
    • 药物遗传基因适合性预测生物标记检验
    • 药物诊断检验
    • 精密癌症治疗
    • 液态生物检体为基础非侵入性癌症分子诊断
    • 循环肿瘤细胞(CTC)检验
    • 胞外体定序
    • 次世代定序检验
  • 市场分析
  • 生物标记产品供应商

第6章 心血管生物标记

  • 概要
  • 心血管疾病的主要生物标记
  • 最近的趋势
    • 高敏感度肌钙蛋白 (hs-cTn)
    • 利钠肽 (BNP/NT-proBNP)
    • 发炎生物标记
    • 代谢和脂质相关生物标记
    • 新兴生物标记和多组学方法
    • 人工智慧与机器学习的整合
  • 市场分析
  • 生物标记产品供应商

第7章 临床化学生物标记

  • 概要
  • 临床化学的主要生物标记
    • 电解质和血气
    • 尿液检查
    • 工作站免疫检测检验
    • 甲状腺检验
    • 生殖能力及其他生物标记
  • 最近的趋势
  • 市场分析
  • 生物标记产品供应商

第8章 神经学的生物标记

  • 概要
  • 神经疾病的主要生物标记
  • 最近的趋势
    • 阿兹海默症血液检测的革命
    • 创伤性脑损伤 (TBI) 生物标记的进展
    • 数位神经生物标记与人工智慧/机器学习的整合
    • 其他神经系统疾病的生物标记疾病
    • 多组学和液体活检方法
  • 市场分析
    • 生物标记产品供应商

第9章 自体免疫生物标记

  • 概要
  • 自体免疫疾病的主要生物标记
  • 最近的趋势
    • 超越传统自体抗体
    • 用于预测疾病进展和治疗反应的生物标记
  • 市场分析
  • 生物标记产品供应商

第10章 其他的生物标记

  • 概要
  • 其他的疾病重要的生物标记
    • 糖尿病和代谢生物标记
    • 怀孕和生殖生物标记
    • 肾臟疾病
    • 遗传性疾病
    • 囊性纤维化
    • 唐氏症
    • 镰状细胞疾病
    • 戈谢病
    • 家族性高胆固醇血症
    • 肌肉营养不良症
    • 血友病
    • 血管性血友病
    • 糖尿病视网膜病变纤维瘤病
    • 多囊性肾病变
    • 脊髓性肌肉萎缩症
    • 克氏症候群
    • 卡纳万病
    • 脑性麻痹
    • 安格尔曼症候群 (AS)
    • 其他遗传性疾病
    • 甲状腺疾病
    • 所有其他生物标记
    • 骨病生物标记
    • 胃肠道生物标记
    • 呼吸系统生物标记物
    • 粪便钙卫蛋白
    • 市场分析

第11章 企业简介

  • Abbott Diagnostics
  • Asuragen (Bio-Techne)
  • Becton Dickinson, and Company
  • Bio-Rad Laboratories
  • Biocartis
  • Biodesix
  • bioMerieux
  • Biotheranostics, Inc. (Hologic)
  • Danaher Corporation
  • DiaSorin Group
  • Exact Sciences
  • Exosome Diagnostics (Bio-Techne)
  • Illumina
  • Myriad Genetics
  • QuidelOrtho
  • Qiagen
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Inostics
  • Thermo Fisher Scientific
简介目录
Product Code: 25-074KA

Kalorama Information's "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031" provides a comprehensive analysis of the worldwide clinical diagnostic biomarker market, with forecasts from 2022 through 2031. The report examines diagnostic substances and tests used for disease detection, therapy selection, disease monitoring, and evaluation of treatment effectiveness across seven major product categories: infectious diseases, cancer, cardiovascular diseases, general clinical chemistry analytes, neurological conditions, autoimmune conditions, and other conditions such as diabetes, metabolic disorders, fertility, pregnancy, kidney disorders, inherited diseases, and thyroid conditions.

Global and regional sales data-along with projections for the U.S., Europe, China, India, and Japan-are provided for each category and major subgroup. All market values reflect end-user spending on biomarker-related reagents, test kits, and consumables, excluding the value of diagnostic instruments. Data are compiled from extensive primary interviews with manufacturers, laboratory professionals, and industry experts, as well as secondary sources including government statistics, trade associations, company filings, and Kalorama publications.

The report explores key industry drivers such as aging populations, targeted therapy adoption, diagnostic test market expansion, and advances in technologies including mass spectrometry, next-generation sequencing, and bioinformatics. Coverage includes the role of biomarkers in personalized and precision medicine, trends in pharmacogenomics, automation, reimbursement, and innovation pipelines. Detailed competitive analysis profiles leading IVD companies and specialized biomarker firms, highlighting commercialized products, emerging technologies, and market positioning.

With in-depth segmentation, market trends, and strategic insights, "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 (Tumor Markers, Kidney Disorder Markers, Inherited Disease Markers, Cardiac Markers, Neurological Markers, Autoimmune Disorders, Infectious Disease, and Other Markers)" serves as an essential resource for companies competing in the biomarker space or seeking to enter this high-growth market.

Table of Contents

Chapter 1: Introduction

  • About Kalorama Information
  • Report Coverage
  • Methodology
    • Sources of Information

Chapter 2: Executive Summary

  • Table 2-1: Global Biomarker Sales, by Product Group & Region, 2022-2031 ($ million) (Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other) & (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)

Chapter 3: Market Environment & Analysis

  • Overview
    • Demographic Patterns
    • Total Population
    • Population Aged 65 Years & Older
    • World Healthcare Trends
    • Health Expenditures
    • Hospitals
    • Physicians
    • Patient Activity
    • Hospital Admissions
    • Surgical Procedures
    • Outpatient Consultations
      • Table 3-1: Global Demographic & Healthcare Indicators, 2022-2031 (World Population, Healthcare Expenditures, Healthcare Resources, and Healthcare Activity)
    • Global Economic Climate
  • Biomarker Technologies
    • The Rising Role of AI and Machine Learning in Biomarker Analysis
  • Biomarker Market Analysis
    • Key Market Trends
    • Biomarker Product Markets
      • Table 3-2: Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
      • Figure 3-1: Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
      • Figure 3-2: Global Biomarker Share, by Product Group, 2025 vs. 2031 (%) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
    • Geographical Markets
      • Table 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific (China, Japan, Other), Central & South America, Eastern & Western Europe, North America (U.S., Canada, Mexico))
      • Figure 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
      • Figure 3-4: Global Biomarker Share, by Region, 2025 vs. 2031 (%) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)

Chapter 4: Infectious Disease Biomarkers

  • Overview
  • Infectious Disease Biomarker Technologies
  • Key Biomarkers for Infectious Disease
    • Respiratory Diseases
      • Table 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
      • Figure 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
      • Figure 4-2: Global Respiratory Disease Biomarker Share, by Condition, 2025 (%)
      • Table 4-2: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
      • Figure 4-3: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
      • Figure 4-4: Global Respiratory Disease Biomarker Share, by Technology, 2025 (%) (Laboratory Immunoassay, Molecular, POC)
    • COVID-19
    • Pneumonia
    • Influenza
    • Group A Streptococcus Infections
    • Tuberculosis
    • Other Respiratory Infections
    • Healthcare-Associated Infections (HAIs)
    • Clostridioides difficile (c. diff)
    • Sepsis
    • Staphylococcus aureus
    • Enterococcus
    • Other Healthcare-Associated Infections
      • Table 4-3: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
      • Figure 4-5: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
      • Figure 4-6: Global Healthcare-Associated Infections (HAIs) Biomarker Share, by Type, 2025 (%) (C. diff, Enterococci, Sepsis, Staph, Other)
    • Hepatitis
      • Table 4-4: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
      • Figure 4-7: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
      • Figure 4-8: Global Hepatitis Biomarker Share, by Type, 2025 (%) (Hepatitis B, Hepatitis C, Other Types)
    • HIV
      • Table 4-5: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
      • Figure 4-9: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
      • Figure 4-10: Global HIV Biomarker Share, by Technology, 2025 (%) (Immunoassay, Molecular, Rapid POC)
    • Sexually Transmitted Diseases (STDs)
    • Human Papillomavirus (HPV)
    • Chlamydia/Gonorrhea (CT/NG)
    • Trichomoniasis
    • Herpes Simplex Virus (HSV-1 & HSV-2)
    • Other Sexually Transmitted Diseases
    • Syphilis
    • Balanitis
    • Chancroid
    • Molluscum Contagiosum
    • Pelvic Inflammatory Disease (PID)
    • Pubic Lice
    • Scabies
    • Vaginitis
      • Table 4-6: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
      • Figure 4-11: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
      • Figure 4-12: Global STD Biomarker Share, by Type, 2025 (%) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
    • TORCH
      • Table 4-7: Global TORCH Biomarker Sales, 2022-2031 ($ million)
      • Figure 4-13: Global TORCH Biomarker Sales, 2022-2031 ($ million)
    • Other Infectious Diseases
    • Malaria
    • Lyme Disease
    • H. pylori
    • Dengue
    • All Other Disease Biomarkers
    • Chagas Disease
    • Cyclosporiasis
    • Cysticercosis
    • Ebola
    • Hantavirus
    • Ringworm
    • West Nile Virus (WNV)
    • Zika Virus
    • Sales of Other Infectious Disease Biomarkers
      • Table 4-8: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
      • Figure 4-14: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
      • Figure 4-15: Global Other Infectious Disease Biomarker Share, by Type, 2025 (%) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
  • Market Analysis
    • Table 4-9: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
    • Figure 4-16: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
    • Figure 4-17: Global Infectious Disease Biomarker Share, by Major Product Group, 2025 (%) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
    • Table 4-10: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
    • Figure 4-18: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
    • Figure 4-19: Global Infectious Disease Biomarker Share, by Technology, 2025 (%) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
  • Biomarker Product Suppliers

Chapter 5: Cancer Biomarkers

  • Overview
  • Key Biomarkers for Cancer
    • Table 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
    • Figure 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
    • Figure 5-2: Global Cancer Biomarker Share, by Type, 2025 (%) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
  • Recent Developments
    • Predictive Biomarker Tests for Drug-Gene Match
    • Pharmacodiagnostic Tests
    • Precision Cancer Therapy
    • Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
    • Circulating Tumor Cell (CTC) Tests
    • Exosome Sequencing
    • Next-Generation Sequencing Tests
  • Market Analysis
    • Table 5-2: Global Cancer Biomarker Sales, by Condition, 2022-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
    • Figure 5-3: Global Cancer Biomarker Sales, by Condition, 2025-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
    • Figure 5-4: Global Cancer Biomarker Share, by Condition, 2025 (%) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
  • Biomarker Product Suppliers

Chapter 6: Cardiovascular Biomarkers

  • Overview
  • Key Biomarkers for Cardiovascular Conditions
  • Recent Developments
    • High-Sensitivity Troponins (hs-cTn)
    • Natriuretic Peptides (BNP/NT-proBNP)
    • Inflammatory Biomarkers
    • Metabolic and Lipid-Related Biomarkers
    • Emerging Biomarkers and Multi-Omics Approaches
    • Integration of AI and Machine Learning
  • Market Analysis
    • Table 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
    • Figure 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
    • Figure 6-2: Global Cardiovascular Biomarker Share, by Product Group, 2025 (%) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
  • Biomarker Product Suppliers

Chapter 7: Clinical Chemistry Biomarkers

  • Overview
  • Key Biomarkers for Clinical Chemistry
    • Electrolytes and Blood Gases
    • Urinalysis
    • Workstation Immunoassay Tests
    • Thyroid Testing
    • Fertility and Other Biomarkers
  • Recent Developments
  • Market Analysis
    • Table 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
    • Figure 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
    • Figure 7-2: Global Clinical Chemistry Biomarker Share, by Product Group, 2025 (%) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
  • Biomarker Product Suppliers

Chapter 8: Neurological Biomarkers

  • Overview
  • Key Biomarkers for Neurological Conditions
  • Recent Developments
    • Revolution in Alzheimer's Disease Blood Tests
    • Advances in Traumatic Brain Injury (TBI) Biomarkers
    • Digital Neuro Biomarkers and AI/ML Integration
    • Biomarkers for Other Neurological Disorders
    • Multi-Omics and Liquid Biopsy Approaches
  • Market Analysis
    • Table 8-1: Global Neurological Biomarker Sales, by Product Group, 2022-2031 ($ million) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
    • Figure 8-1: Global Neurological Biomarker Sales, by Product Group, 2022-2031 ($ million) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
    • Figure 8-2: Global Neurological Biomarker Share, by Product Group, 2025 (%) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
    • Biomarker Product Suppliers

Chapter 9: Autoimmune Biomarkers

  • Overview
  • Key Biomarkers for Autoimmune Diseases
  • Recent Developments
    • Expanding Beyond Traditional Autoantibodies
    • Biomarkers for Predicting Disease Progression and Treatment Response
  • Market Analysis
    • Table 9-1: Global Autoimmune Biomarker Sales, by Product Group, 2022-2031 ($ million) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
    • Figure 9-1: Global Autoimmune Biomarker Sales, by Product Group, 2022-2031 ($ million) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
    • Figure 9-2: Global Autoimmune Biomarker Share, by Product Group, 2025 (%) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
  • Biomarker Product Suppliers

Chapter 10: Other Biomarkers

  • Overview
  • Key Biomarkers for Other Conditions
    • Diabetes & Metabolic Biomarkers
    • Fertility & Pregnancy Biomarkers
    • Kidney Disorders
    • Inherited Diseases
    • Cystic Fibrosis
    • Down Syndrome
    • Sickle Cell Disease
    • Gaucher Disease
    • Familial Hypercholesterolemia
    • Muscular Dystrophy
    • Hemophilia
    • Von Willebrand Disease
    • Neurofibromatosis
    • Polycystic Kidney Disease
    • Spinal Muscular Atrophy
    • Klinefelter Syndrome
    • Canavan Disease
    • Cerebral Palsy
    • Angelman Syndrome (AS)
    • Other Inherited Diseases
    • Thyroid Conditions
    • All Other Biomarkers
    • Bone Disease Biomarkers
    • Gastrointestinal Biomarkers
    • Respiratory Biomarkers
    • Fecal Calprotectin
    • Market Analysis
      • Table 10-1: Other Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)
      • Figure 10-1: Other Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)
      • Figure 10-2: Other Global Biomarker Share, by Product Group, 2025 (%) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)

Chapter 11: Company Profiles

  • Table 11-1: IVD Biomarker-Related Sales of Selected Industry Leaders, 2024 ($ million)
  • Abbott Diagnostics
    • Company Overview
    • Point-of-Care Tests
    • Core Laboratory
    • Molecular Assays
    • Companion Diagnostics
    • Liquid Biopsy
    • Financial
  • Asuragen (Bio-Techne)
    • Company Overview
    • Financial
  • Becton Dickinson, and Company
    • Company Overview
    • Financial
  • Bio-Rad Laboratories
    • Company Overview
    • Financial
  • Biocartis
    • Company Overview
    • Financial
  • Biodesix
    • Company Overview
    • Financial
  • bioMerieux
    • Company Overview
    • Financial
  • Biotheranostics, Inc. (Hologic)
    • Company Overview
    • Financial
  • Danaher Corporation
    • Company Overview
    • Cepheid
    • Radiometer
    • Beckman Coulter
    • Leica Biosystems
    • Financial
  • DiaSorin Group
    • Company Overview
    • Financial
  • Exact Sciences
    • Company Overview
    • Financial
  • Exosome Diagnostics (Bio-Techne)
    • Company Overview
    • Financial
  • Illumina
    • Company Overview
    • Financial
  • Myriad Genetics
    • Company Overview
    • Financial
  • QuidelOrtho
    • Company Overview
    • Financial
  • Qiagen
    • Company Overview
    • Precision Medicine / Companion Diagnostics
    • Liquid Biopsy
    • Financial
  • Roche Diagnostics
    • Company Overview
    • Molecular Testing
    • HPV and Cervical Cancer Screening
    • Immunohistochemistry - IHC
    • Companion Diagnostics
    • Circulating Tumor Cells
    • Financial
  • Siemens Healthineers
    • Company Overview
    • Financial
  • Sysmex Inostics
    • Company Overview
    • Financial
  • Thermo Fisher Scientific
    • Company Overview
    • Financial